Alimera Sciences announces pricing for public stock offering

Alimera Sciences recently announced the pricing of an underwritten public offering of 18 million shares of its common stock at a price to the public of $1.40 per share. The gross proceeds of the stock sale are expected to be approximately $25.2 million, not including the underwriters’ 30-day option to purchase up to an additional 900,000 shares of the common stock at the public offering price. The proceeds are expected to fund the continued commercialization of Iluvien and for working capital and other general corporate purposes, according to an Alimera Sciences press release.